Insulin treatment is a major risk factor for hypoglycaemia in those with CKD, and less stringent HbA1c targets may be appropriate in individuals who experience hypoglycaemia in view of its association with increased mortality [6, 25]. The gene discussed is INS; the disease is chronic kidney disease.